Deerfield Capital

Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. Its services are provided using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistant bacteria.

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

ConcertoCare specializes in delivering primary and complex care to seniors and other adult patients, focusing on those with unmet health and social needs. The company employs three distinct in-home care models that are enhanced by its proprietary population health and analytics engine. By utilizing physician-led interdisciplinary teams, ConcertoCare aims to improve patient outcomes and reduce overall healthcare costs. The organization integrates expertise from fields such as home-based geriatric medicine, digital health, and palliative care, offering clinical decision support tools to facilitate effective care delivery. Through this innovative approach, ConcertoCare addresses the diverse needs of its patient population, striving for enhanced health management.

GrayBug is a pharmaceutical company that develops transformative medicines for ocular diseases. They also develop therapies for inflammatory diseases with unmet needs. Their proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

Revolution Medicines is a clinical-stage precision oncology company dedicated to developing innovative therapies targeting challenging cancer pathways, particularly the RAS and mTOR signaling pathways. The company utilizes a unique approach that reconfigures natural substances into optimized drug candidates, building on the pioneering work of its founder, Martin D. Burke. Revolution Medicines has established an exclusive licensing agreement with the University of Illinois to utilize and further develop this transformative synthetic technology. Among its key product candidates are RMC-4630, a SHP2 inhibitor, and various programs within its RAS(ON) portfolio, along with SOS1 and 4EBP1/mTORC1 initiatives. The company's focus on harnessing complex natural products to create refined, effective therapies positions it to address significant unmet medical needs in oncology.

Acutus Medical, Inc. is a company focused on managing cardiac arrhythmias through the development of advanced medical technologies. Founded in 2011 and based in Carlsbad, California, it designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product lineup includes the AcQMap console for advanced imaging, navigation, and mapping, as well as various diagnostic and therapeutic devices such as diagnostic catheters, ablation catheters, and access devices. Acutus Medical's offerings also feature software solutions that enhance mapping accuracy and procedure efficiency. The company collaborates with medical scientists and engineers in the U.S. and Europe to innovate and improve treatment methods for complex cardiac arrhythmias, serving hospitals and electrophysiologists globally.

Acutus Medical, Inc. is a company focused on managing cardiac arrhythmias through the development of advanced medical technologies. Founded in 2011 and based in Carlsbad, California, it designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product lineup includes the AcQMap console for advanced imaging, navigation, and mapping, as well as various diagnostic and therapeutic devices such as diagnostic catheters, ablation catheters, and access devices. Acutus Medical's offerings also feature software solutions that enhance mapping accuracy and procedure efficiency. The company collaborates with medical scientists and engineers in the U.S. and Europe to innovate and improve treatment methods for complex cardiac arrhythmias, serving hospitals and electrophysiologists globally.

Itamar Medical Ltd. is a medical device company based in Caesarea, Israel, specializing in the research, development, marketing, and sale of non-invasive medical devices for the cardiology market. Founded in 1997, the company utilizes its proprietary Peripheral Arterial Tone (PAT) signal technology to create devices that assess various cardiovascular and respiratory conditions. Its flagship products include the WatchPAT device, which facilitates home testing for sleep disorders such as obstructive sleep apnea, and the EndoPAT device, which is designed to diagnose endothelial dysfunction and evaluate the risk of coronary artery disease. Itamar Medical operates across multiple regions, including the United States, Europe, Canada, Japan, and the Asia Pacific. The company also collaborates with SoClean Inc. to enhance the distribution of its home sleep apnea test and digital health services through direct-to-consumer channels.

Stelexis Therapeutics, LLC is engaged in the research and development of innovative therapies targeting pre-cancerous stem cells. Founded in 2017 and based in New York, the company utilizes a proprietary drug discovery platform to identify pre-cancerous stem and progenitor cells that contribute to the development of primary and recurrent tumors. Its focus is on developing cancer treatments that specifically target pre-cancerous events associated with hematopoietic malignancies, such as acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors. By addressing these early-stage cancer cells, Stelexis Therapeutics aims to improve therapeutic interventions and reduce the risk of relapse in patients.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.

Cabaletta Bio is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, specializing in the discovery and development of engineered T cell therapies aimed at treating B cell-mediated autoimmune diseases. The company's proprietary technology employs chimeric autoantibody receptor (CAAR) T cells that selectively target and eliminate pathogenic B cells responsible for producing harmful autoantibodies, while preserving healthy B cells that are vital to immune function. The lead product candidate, DSG3-CAART, is currently undergoing Phase I clinical trials for the treatment of mucosal pemphigus vulgaris, a rare autoimmune skin disorder, and Hemophilia A with Factor VIII alloantibodies. Additionally, Cabaletta has a pipeline that includes MuSK-CAART for myasthenia gravis and FVIII-CAART for Hemophilia A, both at various stages of development. The company has established collaborations with the University of Pennsylvania and research agreements with the University of California, enhancing its research and development efforts. Founded in 2017, Cabaletta Bio was previously known as Tycho Therapeutics, Inc. before rebranding in 2018.

NeoChord, Inc. is a medical technology company based in St. Louis Park, Minnesota, that focuses on developing innovative devices for the treatment of degenerative mitral valve disease (DMR). Founded in 2007, the company has created the NeoChord Artificial Chordae Delivery System, a disposable device designed for minimally invasive mitral valve repair. This system allows surgeons to replace damaged chordae through a small incision of 2 to 3 inches between the ribs, enabling the procedure to be performed on a beating heart. This approach contrasts sharply with traditional methods, which typically involve larger incisions and stopping the heart, thus reducing recovery time and associated complications. NeoChord's technology aims to improve surgical outcomes for patients suffering from severe mitral regurgitation, which can lead to serious conditions such as atrial fibrillation and congestive heart failure.

Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Orchard Therapeutics is a biopharmaceutical company based in the United Kingdom that specializes in developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which modifies a patient's own hematopoietic stem cells to create a targeted treatment administered in a single dose. Orchard's portfolio includes Strimvelis, the first autologous gene therapy approved by the European Medicines Agency for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Additionally, it is advancing clinical programs for various conditions, including metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has an extensive preclinical pipeline targeting mucopolysaccharidosis types I, IIIA, and IIIB. Orchard Therapeutics collaborates with leading institutions in gene therapy research, enhancing its efforts to transform the lives of patients with rare diseases in the UK, European Union, and the United States. Founded in 2015 and headquartered in London, it aims to provide sustainable clinical benefits through its innovative therapies.

MedAvail Holdings, Inc. is a technology-enabled pharmacy company based in Mississauga, Canada. It integrates automated pharmacy services into clinics and other healthcare points through its proprietary technology. The company offers comprehensive services via its robotic dispensing platform, the MedAvail MedCenter, and includes home delivery operations. MedAvail primarily operates SpotRx, a telehealth-enabled retail pharmacy that provides remote pharmacist consultations through an on-site dispensing kiosk, catering mainly to Medicare patients in the United States. Additionally, the Pharmacy Technology segment focuses on developing and commercializing the MedCenter for direct sale or lease to third-party customers.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

Johns Hopkins University, a private research university located in Baltimore, Maryland, was established in 1876 and is recognized as the first research university in the United States. Founded with a significant philanthropic bequest from entrepreneur and abolitionist Johns Hopkins, the institution has played a pivotal role in advancing higher education by integrating teaching and research. Over the years, Johns Hopkins has maintained a strong emphasis on research, leading all U.S. universities in annual research and development expenditures. The university operates additional graduate campuses in Italy, China, and Washington, D.C., enhancing its global presence. The Office of Investment Management oversees the university's endowment, which supports a range of initiatives including scholarships, professorships, and research programs, primarily funded through earnings from investments. The endowment employs an alternative investment strategy focusing on venture capital, further contributing to the university's mission of academic excellence and public service.

Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

SteadyMed Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutic products for pain relief and chronic conditions. The company is known for its PatchPump, a customizable, pre-filled, and pre-programmed disposable delivery platform designed for large volume and viscous formulations. Key offerings include Trevyent, a single-use PatchPump pre-filled with treprostinil for treating pulmonary arterial hypertension, and SMT-201, which enables subcutaneous delivery of Ketorolac, a non-steroidal anti-inflammatory drug. Additionally, SMT-301 delivers bupivacaine directly into surgical wounds for effective local pain relief. Founded in 2005 and headquartered in San Ramon, California, with a research and development center in Rehovot, Israel, SteadyMed operates as a subsidiary of United Therapeutics Corporation. The company collaborates with pharmaceutical and device partners to tailor applications of its drug-infusion patches to meet specific therapeutic needs.

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Their lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. They believe that setmelanotide, for which they have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin 4, or MC4, pathway deficiencies. The MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight, and peptide therapeutics are uniquely suited to activating this target.

Chondrial Therapeutics s a clinical-stage biotechnology company focused on the treatment of rare diseases. It is dedicated to the pursuit of scientific research leading to the treatment for Friedreich’s Ataxia and other mitochondrial diseases.

Vensun Pharmaceuticals, Inc. is a pharmaceutical company based in Yardley, Pennsylvania, that specializes in developing a diverse portfolio of generic prescription products across various dosage forms and therapeutic categories. Founded in 2011, the company is focused on co-developing these products through strategic partnerships both domestically and internationally. Vensun has filed multiple Abbreviated New Drug Applications (ANDAs) with the FDA and currently has over 30 products in active development. The company is also pursuing additional opportunities for partnerships, strategic alliances, and product acquisitions to further enhance its development portfolio, aiming to provide enhanced pharmaceuticals to clinicians and healthcare professionals in the U.S. generic market.

ConcertoCare specializes in delivering primary and complex care to seniors and other adult patients, focusing on those with unmet health and social needs. The company employs three distinct in-home care models that are enhanced by its proprietary population health and analytics engine. By utilizing physician-led interdisciplinary teams, ConcertoCare aims to improve patient outcomes and reduce overall healthcare costs. The organization integrates expertise from fields such as home-based geriatric medicine, digital health, and palliative care, offering clinical decision support tools to facilitate effective care delivery. Through this innovative approach, ConcertoCare addresses the diverse needs of its patient population, striving for enhanced health management.

Aerie Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases, including glaucoma, dry eye, and retinal conditions. The company's key products include Rhopressa, a once-daily eye drop designed to lower elevated intraocular pressure in patients with glaucoma or ocular hypertension, and Rocklatan, a fixed-dose combination of Rhopressa and latanoprost, also aimed at reducing intraocular pressure in open-angle glaucoma patients. Additionally, Aerie is developing AVX-012, a clinical-stage candidate for dry eye, alongside AR-1105 and AR-13503, which are sustained-release implants targeting retinal diseases. Founded in 2005, Aerie Pharmaceuticals is headquartered in Durham, North Carolina, and has a collaborative research agreement with DSM, reflecting its commitment to advancing eye care solutions.

Nuo Therapeutics is a biotechnology company based in Gaithersburg, Maryland, that specializes in regenerative therapies aimed at chronic wound care. Founded in 1998 and formerly known as Cytomedix, Nuo Therapeutics develops, commercializes, and markets cell-based technologies that utilize the body’s natural healing processes. The company's flagship product, the AutoloGel System, produces platelet-rich plasma gel from a patient's own blood and is FDA-cleared for various exuding wounds. Nuo Therapeutics generates revenue primarily from the sale of its Aurix product to hospital outpatient wound care clinics and private practice physicians. The company focuses on addressing critical areas such as wound care, inflammation, and angiogenesis.

Alphatec Spine is a medical technology company focused on developing and manufacturing innovative solutions for spine surgery. Established in 1990 and headquartered in Carlsbad, California, the company specializes in products designed to address a range of spine disorders, particularly those affecting the aging population. Its diverse product portfolio includes lateral lumbar interbody fusion systems, posterior fixation systems, and anterior cervical plating systems, as well as various interbody fusion products. Alphatec Spine also offers biologics, such as amniotic tissue barriers and demineralized bone matrix, alongside minimally invasive surgical solutions. The company markets its products primarily in the United States and has a global presence through direct sales and independent distributors in Europe, the Middle East, Africa, and parts of Asia and Latin America. Formerly known as Alphatec Manufacturing, Alphatec Spine has expanded its international footprint with additional locations in Japan, Hong Kong, France, the United Kingdom, and Germany.

MannKind Corporation is a biopharmaceutical company based in Westlake Village, California, that specializes in the development and commercialization of inhaled therapeutic products for patients with diabetes and pulmonary arterial hypertension. The company's flagship product, Afrezza, is an ultra-rapid-acting inhaled insulin designed to enhance glycemic control in adults with diabetes. This innovative product is delivered through a small, portable inhaler and provides an alternative to traditional insulin delivery methods. Additionally, MannKind has a collaboration agreement with United Therapeutics Corporation to develop a dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. Founded in 1991, MannKind is committed to advancing inhaled therapies to improve patient outcomes in chronic diseases.

Raptor Pharmaceuticals is a biotechnology company based in Novato, California, focused on the development of therapies for debilitating and life-threatening diseases. The company is engaged in the discovery, research, and preclinical development of drug candidates targeting brain disorders, neurodegenerative diseases, genetic disorders, and cancer. Raptor's clinical-stage products include DR Cysteamine, which is undergoing Phase IIb trials for nephropathic cystinosis and Phase IIa trials for non-alcoholic steatohepatitis, as well as Convivia for ALDH2 deficiency and other candidates for Huntington's disease and various forms of pain. Additionally, Raptor is developing preclinical products such as HepTide for hepatocellular carcinoma and hepatitis C, WntTide for breast cancer, and NeuroTrans for neurodegenerative diseases. The company collaborates with the University of California, San Diego, on clinical studies involving its drug candidates. Founded in 2005, Raptor Pharmaceuticals aims to address significant unmet medical needs through its innovative therapeutic approaches.

Hana Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing new, differentiated cancer therapies designed to improve and enable current standards of care. The company's lead product candidate, Marqibo(R), potentially treats acute lymphoblastic leukemia and lymphomas.

CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.

BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.

CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.

Clinical-stage biotech focused on cardiovascular, central nervous system, inflammatory and metabolic diseases. Their leading drug candidate is lorcaserin hydrochloride, which recently received positive data from a clinical trial. They are headquartered in San Diego, CA.

NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide. NitroMed is conducting a late-stage confirmatory trial of our lead nitric oxide-enhancing drug, BiDil, for the treatment of heart failure in African Americans.

PacBio designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes.

Tengion is a clinical-stage biotechnology company focused on regenerative medicine, specializing in the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Tengion Neo-Bladder Augment, aimed at treating children with neurogenic bladder due to spina bifida and adults with neurogenic bladder resulting from spinal cord injury. Tengion's innovative approach seeks to eliminate the need for donor organs or anti-rejection medications by creating living cellular products that can regenerate or replace damaged tissues and organs. Additionally, the company has an investigational new drug application for its Neo-Urinary Conduit and plans to initiate a Phase 1 clinical trial for bladder cancer patients requiring bladder removal. Through its proprietary technology, Tengion aims to enhance patient outcomes by offering alternative solutions for organ and tissue repair.

Novare Surgical Systems, Inc. develops, manufactures, and markets devices for minimally invasive surgery. It offers motion hand-held laparoscopic instruments, which includes graspers, dissectors, cautery, and needle holders. The company's products are used in acid reflux treatment, adrenal gland removal, colon resection, gastric bypass, hysterectomy, lung lobe removal, ovary removal, prostate removal, achalasia treatment, appendix removal, gall bladder removal, hernia repair, lymph node extraction, kidney removal, pelvic mass removal, and spleen removal procedures. It provides its products through its sales representatives in the United States, Austria, Belgium, Canada, Denmark, Greece, Israel, Italy, Korea, Sweden, Switzerland, and Turkey. Novare Surgical Systems, Inc. was founded in 1999 and is headquartered in Cupertino, California.